Samuel Hellman to Humans
This is a "connection" page, showing publications Samuel Hellman has written about Humans.
Connection Strength
0.422
-
Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766.
Score: 0.031
-
Learning while caring: medicine's epistemology. J Clin Oncol. 2014 Sep 01; 32(25):2804-8.
Score: 0.017
-
Oligometastases revisited. Nat Rev Clin Oncol. 2011 06; 8(6):378-82.
Score: 0.013
-
On first looking into Kutcher's "Contested Medicine": ethical tensions in clinical research. Perspect Biol Med. 2010; 53(2):304-14.
Score: 0.012
-
Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res. 2009 Jan 15; 69(2):383-92.
Score: 0.011
-
Stem-cell biology and cancer therapy: the more things change... J Clin Oncol. 2008 Feb 20; 26(6):821-2.
Score: 0.011
-
Early prostate cancer: hedonic prices model of provider-patient interactions and decisions. Int J Radiat Oncol Biol Phys. 2008 Mar 15; 70(4):1158-68.
Score: 0.010
-
Unintended consequences. Nat Clin Pract Oncol. 2007 Aug; 4(8):439.
Score: 0.010
-
Evolving paradigms and perceptions of cancer. Nat Clin Pract Oncol. 2005 Dec; 2(12):618-24.
Score: 0.009
-
Premise, promise, paradigm and prophesy. Nat Clin Pract Oncol. 2005 Jul; 2(7):325.
Score: 0.009
-
Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):687-94.
Score: 0.009
-
Importance of local control in an era of systemic therapy. Nat Clin Pract Oncol. 2005 Feb; 2(2):60-1.
Score: 0.009
-
Debunking dogma and developing theses. Eur J Cancer. 2005 Mar; 41(4):489-90.
Score: 0.009
-
Excision margins in high-risk malignant melanoma. N Engl J Med. 2004 May 27; 350(22):2305-6; author reply 2305-6.
Score: 0.008
-
Letrozole in breast cancer. N Engl J Med. 2004 Feb 12; 350(7):727-30; author reply 727-30.
Score: 0.008
-
Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer. 2003 Dec 01; 98(11):2351-61.
Score: 0.008
-
Early prostate cancer: clinical decision-making. Lancet. 2003 Mar 22; 361(9362):1045-53.
Score: 0.008
-
Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis. Cancer. 2003 Jan 15; 97(2):359-66.
Score: 0.007
-
An evidence-based analysis of the management of localized prostate cancer. Cancer J. 2002 Jan-Feb; 8(1):40-6.
Score: 0.007
-
Sun Valley summary. Consensus and action items Expedition Inspiration meeting 2000. Breast Cancer Res Treat. 2001 Apr; 66(3):179-82.
Score: 0.007
-
Individual characterisation of the metastatic capacity of human breast carcinoma. Eur J Cancer. 2000 Aug; 36(13 Spec No):1631-9.
Score: 0.006
-
The clinical significance of tumor progression: breast cancer as a model. Cancer J. 2000 Apr; 6 Suppl 2:S131-3.
Score: 0.006
-
Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol. 2000 Feb; 18(3):591-9.
Score: 0.006
-
Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 2000 Jan 15; 60(2):298-304.
Score: 0.006
-
The ethical lessons of managed care applied to clinical trials. Cancer Treat Res. 2000; 102:91-8.
Score: 0.006
-
Aging, progression, and phenotype in breast cancer. J Clin Oncol. 1998 Aug; 16(8):2686-92.
Score: 0.005
-
The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res. 1998 Jul 01; 58(13):2766-71.
Score: 0.005
-
The benefits of mammography are not limited to women of ages older than 50 years. Cancer. 1998 Jun 01; 82(11):2221-6.
Score: 0.005
-
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793.
Score: 0.005
-
Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am. 1998 Jan-Feb; 4(1):27-34.
Score: 0.005
-
Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Res Treat. 1998; 52(1-3):147-58.
Score: 0.005
-
Breast cancer metastatic phenotype as predicted by histologic tumor markers. Cancer J Sci Am. 1997 Jul-Aug; 3(4):224-9.
Score: 0.005
-
Darwin's clinical relevance. Cancer. 1997 Jun 15; 79(12):2275-81.
Score: 0.005
-
Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation. J Clin Oncol. 1997 Jun; 15(6):2329-37.
Score: 0.005
-
Advances in radiation oncology. Lancet. 1997 May; 349 Suppl 2:SII1-3.
Score: 0.005
-
Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst. 1996 Dec 04; 88(23):1764-9.
Score: 0.005
-
Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncol. 1996 Dec; 14(12):3105-11.
Score: 0.005
-
Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones. J Vis Exp. 2016 11 30; (117).
Score: 0.005
-
Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am. 1996 Jul-Aug; 2(4):225-33.
Score: 0.005
-
Radiation oncology. JAMA. 1996 Jun 19; 275(23):1852-3.
Score: 0.005
-
Roentgen Centennial Lecture: discovering the past, inventing the future. Int J Radiat Oncol Biol Phys. 1996 Apr 01; 35(1):15-20.
Score: 0.005
-
The patient and the public good. Monash Bioeth Rev. 1996 Jan; 15(1):S5-10.
Score: 0.005
-
Radiation oncology and the new biology. Cancer J Sci Am. 1995 Sep-Oct; 1(3):174-9.
Score: 0.004
-
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
Score: 0.004
-
Imaging of tumor clones with differential liver colonization. Sci Rep. 2015 Jun 22; 5:10946.
Score: 0.004
-
The patient and the public good. Nat Med. 1995 May; 1(5):400-2.
Score: 0.004
-
Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol. 1995 May; 13(5):1144-51.
Score: 0.004
-
14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
Score: 0.004
-
Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol. 1994 Oct; 12(10):2229-34.
Score: 0.004
-
Clinical cancer research: the past, present and the future. Nat Rev Clin Oncol. 2014 Nov; 11(11):663-9.
Score: 0.004
-
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014 Aug; 31(6):735-48.
Score: 0.004
-
Radiation oncology. JAMA. 1994 Jun 01; 271(21):1712-4.
Score: 0.004
-
The end of inevitability, or Frankenstein and the biological revolution. Pharos Alpha Omega Alpha Honor Med Soc. 1994; 57(2):41-3.
Score: 0.004
-
Dogma and inquisition in medicine. Breast cancer as a case study. Cancer. 1993 Apr 01; 71(7):2430-3.
Score: 0.004
-
Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013 Apr 10; 31(11):1384-90.
Score: 0.004
-
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
Score: 0.004
-
MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011; 6(12):e28650.
Score: 0.003
-
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
Score: 0.003
-
The intellectual quarantine of American medicine. Acad Med. 1991 May; 66(5):245-8.
Score: 0.003
-
Thomas Hodgkin and Hodgkin's disease. Two paradigms appropriate to medicine today. JAMA. 1991 Feb 27; 265(8):1007-10.
Score: 0.003
-
Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81.
Score: 0.003
-
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
Score: 0.003
-
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
Score: 0.002
-
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
Score: 0.002
-
The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer. 2004 May 01; 100(9):1807-13.
Score: 0.002
-
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. Breast Cancer Res Treat. 2003 Jul; 80(2):139-44.
Score: 0.002
-
Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Res Treat. 2003 Mar; 78(1):127-31.
Score: 0.002
-
Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002 Nov; 3(11):665-71.
Score: 0.002
-
Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug; 110(3):403-10.
Score: 0.002
-
NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res. 2000 Dec 15; 60(24):6958-63.
Score: 0.002
-
Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 1996 Oct 01; 56(19):4311-4.
Score: 0.001
-
Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995 Aug; 1(8):786-91.
Score: 0.001